A phase II study of 18F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); Objective and symptomatic responses at 6 and 12 weeks

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 68-74

  O'Brien, M E R ^a   Myerson, J S ^a   Coward, J I G ^a   Puglisi, M ^a   Trani, L ^a   Wotherspoon, A ^a   Sharma, B ^a   Cook, G ^a   Ashley, S ^a   Gunapala, R ^a   Chua, S ^a   Popat, S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Erlotinib; FDG PET CT; NSCLC; Progressive disease; Symptomatic response

Indexed keywords

ERLOTINIB; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; FATIGUE; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 83255184979     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.033     Document Type: Article

References (15)

1. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 2009 947 957
2. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 2005 123 132
3. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 6 2010 521 529
4. H. van Tinteren, O.S. Hoekstra, and E.F. Smit Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial Lancet 359 9315 2002 1388 1393
5. J.F. Vansteenkiste, S.G. Stroobants, and P.J. Dupont Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group J Clin Oncol 17 10 1999 3201 3206
6. N. Al-Sarraf, K. Gately, and J. Lucey Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases Eur J Cardiothorac Surg 34 4 2008 892 897
7. M.P. Mac Manus, R.J. Hicks, and J.P. Matthews Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer J Clin Oncol 21 7 2003 1285 1292
8. F. Lordick, K. Ott, and B.J. Krause PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol 8 9 2007 797 805
9. R.J. Cerfolio, B. Ojha, and S. Mukherjee Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma J Thorac Cardiovasc Surg 125 4 2003 938 944
10. T. Zander, M. Scheffler, and L. Nogova Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography J Clin Oncol 29 13 2011 1701 1708
11. L. Mileshkin, R.J. Hicks, and B.G. Hughes Changes in 18F- fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib Clin Cancer Res 17 10 2011 3304 3315
12. R.P. A'Hern Sample size tables for exact single-stage phase II designs Stat Med 20 6 2001 859 866
13. H. Young, R. Baum, and U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 13 1999 1773 1782
14. P.A. Ellis, I.E. Smith, and J.R. Hardy Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer Br J Cancer 71 2 1995 366 370
15. I.E. Smith, M.E. O'Brien, and D.C. Talbot Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol 19 5 2001 1336 1343